Growth Metrics

Eli Lilly (LLY) Capital Expenditures Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -27.23%
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 51.53%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 6.72%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 14.83%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -0.53%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 27.44%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 2.39%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -27.39%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 7.67%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 51.53%
Dec 31, 2025 71.98%
Sep 30, 2025 50.11%
Jun 30, 2025 65.98%
Mar 31, 2025 60.47%
Dec 31, 2024 72.52%
Sep 30, 2024 58.88%
Jun 30, 2024 47.55%
Mar 31, 2024 48.65%
Dec 31, 2023 33.05%
Sep 30, 2023 35.15%
Jun 30, 2023 37.85%
Mar 31, 2023 37.30%
Dec 31, 2022 15.32%
Sep 30, 2022 32.82%
Jun 30, 2022 15.58%
Mar 31, 2022 21.50%
Dec 31, 2021 -9.59%
Sep 30, 2021 7.67%
Jun 30, 2021 7.14%
Mar 31, 2021 8.29%
Dec 31, 2020 0.83%
Sep 30, 2020 17.44%
Jun 30, 2020 8.34%
Mar 31, 2020 15.19%
Dec 31, 2019 -7.29%
Sep 30, 2019 5.01%
Jun 30, 2019 -0.70%
Mar 31, 2019 9.70%
Dec 31, 2018 1.22%
Sep 30, 2018 -0.45%
Jun 30, 2018 11.46%
Mar 31, 2018 7.84%
Dec 31, 2017 2.75%
Sep 30, 2017 -6.50%
Jun 30, 2017 -4.56%
Mar 31, 2017 -5.77%
Dec 31, 2016 -4.06%
Sep 30, 2016 -3.58%
Jun 30, 2016 21.62%
Mar 31, 2016 -0.77%
Dec 31, 2015 -2.74%
Sep 30, 2015 14.54%
Jun 30, 2015 7.65%
Mar 31, 2015 13.00%
Dec 31, 2014 16.90%
Sep 30, 2014 19.11%
Jun 30, 2014 22.40%
Mar 31, 2014 25.83%
Dec 31, 2013 22.75%
Sep 30, 2013 15.65%
Jun 30, 2013 -4.01%
Mar 31, 2013 8.07%
Dec 31, 2012 17.18%
Sep 30, 2012 1.45%
Jun 30, 2012 0.49%
Mar 31, 2012 -5.93%